A common diabetes drug is making headlines for its unexpected effects on the brain. Metformin may do more than control blood sugar. New research suggests it could also influence memory, thinking, and dementia risk.
Metformin has been the first-line treatment for type 2 diabetes for over 60 years. It works mainly by lowering glucose production in the liver. But scientists now believe it also acts on the brain. Recent studies show it targets a protein called Rap 1, which plays a key role in brain function and blood sugar regulation.
Type 2 diabetes raises the risk of cognitive decline and dementia. Poor blood sugar control can damage brain cells over time. Metformin may help protect the brain by improving insulin sensitivity and reducing inflammation. It activates a pathway called AMPK, which supports brain cell energy and health.
However, findings remain mixed. Some studies suggest that metformin users face a lower risk of dementia. An Australian study found an 81% drop in dementia risk among diabetic patients on the drug. Other research warns of possible downsides. A 2014 study linked metformin use to worse cognitive performance in some patients. Vitamin B12 deficiency, a known side effect of long-term use, may also harm brain health.
When did this emerge? Interest grew after mouse studies showed clear brain changes. UK Biobank is now analysing brain scans of metformin users to settle the debate. Results are expected soon. These will show if the drug changes brain structure or function in humans.
Current status shows cautious optimism. The NHS continues to prescribe metformin as the gold standard for diabetes care. Doctors say benefits outweigh risks for most patients. Yet, they advise regular B12 checks for long-term users. Experts call for more human trials to clarify the drug’s full impact on cognition.
Dr. Sarah Alan, a UK-based endocrinologist, noted, “The research is a long way from the clinic, but it is important.” She added that understanding how metformin affects the brain could open new treatment paths for both diabetes and dementia.
For now, patients should not stop taking their medication. Metformin remains safe and effective for blood sugar control. But the new findings highlight the need for personalised care. Age, genetics, and lifestyle may influence how each person’s brain responds to the drug.
The UK’s ageing population makes this issue urgent. With dementia cases rising, any drug that could slow cognitive decline is valuable. Metformin is cheap, widely available, and already trusted by millions. If proven to protect the brain, it could become a dual-purpose therapy.
Scientists plan to dive deeper into human data next. They will study how factors like sex, genetics, and diet shape responses. This could help identify who benefits most and who might face risks.